Area Monitoring Overview 

Area monitoring is one of the most important components of ensuring individual and community safety. Read this brief area monitoring overview to learn more.

MAVEN Analyzer Wins 2023 R&D 100 Award 

R&D World magazine announced the 100 winners of the 2023 R&D 100 Awards. 908 Devices’ MAVEN™ was one of the 21 award winners in the Analytical/Test category. Read More.

Grim Realities: Why Illegally Grown Marijuana Is Wreaking Havoc on Our Environment 

As of April 2023, 22 states and the District of Columbia have legalized marijuana for recreational use while 37 states (and DC) have legalized it for “medical” purposes. As more states consider legalizing, and other states attempt to regulate a drug that remains illegal under federal law, the black market continues to thrive.

Understanding Public Perception of Xylazine and Synthetic Opioids 

In an attempt to better analyze the public perception of xylazine and synthetic opioids, we surveyed 1,000 U.S. consumers to gauge how informed they are. What we learned is this is not a traditional addiction issue. Read more.

MX908 and the Identification of Fentanyl/Xylazine Mixtures

The MX908 provides coverage of low concentration mixtures of powerful synthetics such as xylazine and 2000+ fentanyl analogs in cutting agents or other, more common, drugs to provide investigators with an important tool to meets today’s counter-drug challenges.

Announcing the 3.4 Software Update New Target Release

SW v3.4 will include three new drug targets and one new explosives target.

Announcing the 3.3 Software Update New Target Release

We just released 3 new targets including a fentanyl analog, cannabinoid and precursor.

New Target Update: Preparing for the Next in Synthetic Opioid Trends, Nitazenes  

We just released another nitazene drug target to empower detection of illicit drugs that contain these toxic substances. MX908 now detects four nitazenes.

One Pill Can Kill: Current and Emerging Drug Threats

The Need For Speed In The Lab

The growth and visibility of new biologic-based therapeutics has created a race to see which new medicines can make it to market first. R&D scientists and bioprocess development teams are under immense pressure to meet global demand for new drugs, while at the same time ensuring safety, quality, and cost efficiencies.

One Pill Can Kill: MX908 and Counterfeit Pills

The DEA has issued a public safety alert warning against a sharp increase in counterfeit pill overdoses in the US. The MX908 excels at identifying such pills.

The Impact and Rising Danger of the Opioid Epidemic

email Subscribe to Our Communications Signup to receive new product updates, technical tips and more.